Quantcast

Latest KRAS Stories

2012-06-13 14:53:48

Targeted cancer cell therapies using man-made proteins dramatically shrink many tumors in the first few months of treatment, but new research from Johns Hopkins scientists finds why the cells all too often become resistant, the treatment stops working, and the disease returns. In a study of 28 advanced colon cancer patients treated with the monoclonal antibody panitumumab, the Johns Hopkins Kimmel Cancer Center team reports that drug-resistance tumor cell mutations appear in the blood of...

2012-06-11 20:08:20

A pair of recent studies describes how pancreatic cancer cells produce a protein that attracts the body's immune cells and tricks them into helping cancer cells grow. The research, published by Cell Press in the June 12th issue of the journal Cancer Cell, also reveals that blocking the protein may be an effective way to treat pancreatic cancer. "We found that simply disabling the ability of tumors to make this molecule leads to a house-of-cards effect that resulted in massive tumor death...

2012-04-26 23:54:58

Researchers trace influence via mouse model that allows oncogene to be turned on and off A genetic mutation that drives the initiation of pancreatic cancer also manipulates metabolic pathways to support tumor growth and progression, scientists report in the journal Cell. This newly discovered role for the Kras oncogene opens up a new category of potential targets for thwarting the influential mutation, which has proved difficult to attack directly, said study co-lead author Haoqiang...

2012-04-04 20:19:43

The results, which highlight the use of a novel drug called ARI-4175, may eventually point to new approaches that can be used in treating other cancers When combined with other treatments, the drug cetuximab–which works by slowing or stopping the growth of cancer cells–has been shown to extend survival in certain types of cancer, including metastatic colorectal cancers. Unfortunately, about 40 percent of colorectal cancer patients–specifically those who carry a mutated...

2012-04-04 20:14:45

Testing patients with non-small cell lung cancer for both mutations and amplifications of the KRAS gene prior to therapy may help to predict response to treatment with antifolates, according to the updated results of a preclinical study presented at the AACR Annual Meeting 2012, held here March 31 - April 4. Patients, especially those with lung cancer, who have KRAS gene mutations have a worse prognosis and do not respond well to targeted therapies, according to Sarah Bacus, Ph.D.,...

2012-04-04 12:16:00

Anurag Singh, PhD, assistant professor in the Department of Pharmacology and Experimental Therapeutics at Boston University School of Medicine has been invited to present his recent work on targeted therapeutics for colon cancer at the American Association of Cancer Research Annual Meeting in Chicago, IL. Singh's seminar, scheduled for Tuesday April 3rd, will be featured in the "Late-Breaking Abstracts Mini-Symposium". This highlights recent and provocative groundbreaking research in cancer...

2012-04-04 10:14:06

Adding the drug cetuximab to a regimen of drugs used for the treatment of patients following surgery for stage III colon cancer did not result in improved disease-free survival, according to a study in the April 4 issue of JAMA. Patients who have surgery for removal of stage III colon cancer have a 50 percent chance of cure. Multiple trials have established the benefit of chemotherapy after surgery in reducing the recurrence risk. "Specifically, [the drugs] leucovorin, fluorouracil, and...

2012-04-02 15:28:44

Fox Chase scientists suggest that the findings could also serve as a new target for treatment Researchers at Fox Chase Cancer Center in Philadelphia have found that a protein associated with other cancers appears to also be important in head and neck cancer, and may consequently serve as a good target for new treatments. The findings will be reported at the AACR Annual Meeting 2012 on Sunday, April 1. The researchers found that patients whose tumors had higher levels of the protein...


Word of the Day
glogg
  • Scandinavian punch made of claret and aquavit with spices and raisins and orange peel and sugar.
This word comes from the Swedish 'glogg,' which is an alteration of 'glodgat,' mulled (wine).
Related